GlaxoSmithKline (GSK) Paper At Center Of Fabricated Data Scandal Is Retracted
12/9/2013 8:28:10 AM
GlaxoSmithKline (NYSE: GSK) says the Nature Medicine journal has retracted an article that contained misleading data tied to the drug maker’s research program in China. GSK recommended withdrawing the article, published in 2010, after concluding an investigation in June that found some data had been misrepresented, London-based Glaxo said in a statement Friday. Five of the named authors, including the head of its Chinese research and development, resigned or were fired following the probe, it said.
Help employers find you! Check out all the jobs and post your resume.
comments powered by